Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.

ABSTRACT:

Introduction

Dupilumab is the first biologic licensed to treat patients with moderate-to-severe atopic dermatitis (AD) who require systemic therapy. PROLEAD was designed to document the real-world effectiveness and safety of dupilumab in patients with moderate-to-severe AD. The present study aims to describe the baseline characteristics of patients treated with dupilumab in Germany.

Methods

PROLEAD is a national, multicentre, prospective, non-interventional study, with a 2-year observation period. Adults with moderate-to-severe AD treated with dupilumab were included. Baseline characteristics, physician assessments, and patient-reported outcomes (PROs) were collected.

Results

The study involved 126 sites throughout Germany. Of 839 patients assessed for eligibility, 82

SUBMITTER: Thaci D 

PROVIDER: S-EPMC9464282 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature